Ayurcann Holdings Corp. (
CSE.AYUR,
OTCQB: AYURF,
Forum) – a leading Canadian cannabis extraction company specializing in the processing and co-manufacturing of pharma grade cannabis and hemp to produce various derivative cannabis 2.0 and 3.0 products in the medical and recreational market – has announced that it has received its flower sales license amendment from Health Canada effective April 19, 2022. The Flower Sales License will allow Ayurcann to sell dried cannabis flower products in Canada through authorized distributors and retailers.
Igal Sudman, Chief Executive Officer of Ayurcann, commented:
With our specialty in extraction and Cannabis 2.0 brands in Vapes and Oils available “throughout Canada, receiving the Flower Sales License is another avenue for Ayurcann to gather market share and pursue higher-margin growth within the cannabis market. With our current suppliers and large volume purchasing power we can leverage our current relationships by offering an expanded portfolio of other products targeted at the value conscious consumer. Our offerings will include pre-rolls and dried flower."
For full story, click
here.
New to investing in Cannabis? Check out Stockhouse tips on How to Invest in Cannabis Stocks and some of our Top Cannabis Stocks.
For more of the latest info on Cannabis, check out the Cannabis Trending News hub. Or, for lively sector discussion, visit Stockhouse’s new Cannabis Bullboards page.
FULL DISCLOSURE: Ayurcann Holdings Corp. is a client of Stockhouse Publishing.